xmlui.ArtifactBrowser.ConfigurableBrowse.title.metadata.authorArtikkelit"Åhman H"

Avidity of IgG antibodies for S. pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugate vaccines and boostered with polysaccharide or conjugate

Anttila M; Eskola J; Åhman H; Käyhty H
J Infect Dis (1998)

Bridging Phase 2 and Phase 3 Pneumococcal Immunologic Data for Future Combination Vaccines

Käyhty H; Åhman H
Clin Infect Dis : 33 (2001)

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media.

Jokinen JT; Åhman H; Kilpi TM; Mäkelä PH; Käyhty H
J Infect Dis : 190 (2004)

Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood

Anttila M; Eskola J; Åhman H; Käyhty H
Vaccine : 15-16 (1999)

Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid

Åhman H; Käyhty H; Vuorela A; Leroy O; Eskola J
Vaccine : 20-21 (1999)

Immunogenicity and Tolerability of a Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 12 Months of Age.

Käyhty H; Åhman H; Eriksson K; Sorberg M; Nilsson L
Pediatr Infect Dis J : 2 (2005)

Kinetics and avidity of antibodies evoked by two pneumococcal conjugate vaccines, PncCRM.and PncOMPC, in the Finnish Otitis Media Vaccine Trial

Ekström N; Åhman H; Verho J; Jokinen J; Väkeväinen M; Kilpi T; Käyhty H
Infect Immun : 1 (2005)

Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants

Åhman H; Käyhty H; Tamminen P; Uistola A; Malinoski F; Eskola J
Pediatr Infect Dis J (1996)

Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children

Käyhty H; Åhman H; Rönnberg P-R; Tillikainen R; Eskola J
J Infect Dis (1995)

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: Randomised, controlled trial of a sevenvalent pneumococcal polysaccharide-meningococcal outer membrane protein c

Kilpi T; Åhman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH
Clin Infect Dis : 9 (2003)

Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid

Korkeila M; Lehtonen H; Åhman H; Leroy O; Eskola J; Käyhty H
Vaccine : 13 (2000)

Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine

Nurkka A; Åhman H; Korkeila M; Jäntti V; Käyhty H; Eskola J
Pediatr Infect Dis J : 1 (2001)

Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT

Nurkka A; Åhman H; Yaich M; Eskola J; Käyhty H
Vaccine : 20 (2001)

Streptococcus pneumoniae capsular polysaccharide - diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory

Åhman H; Käyhty H; Lehtonen H; Leroy O; Froeschle J; Eskola J
Pediatr Infect Dis J (1998)

Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers

Wuorimaa T; Dagan R; Eskola J; Janco J; Åhman H; Leroy O; Käyhty H
Pediatr Infect Dis J : 3 (2001)

Artikkelit - Selaus tekijän mukaan "Åhman H"

Avidity of IgG antibodies for S. pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugate vaccines and boostered with polysaccharide or conjugate ﻿

Bridging Phase 2 and Phase 3 Pneumococcal Immunologic Data for Future Combination Vaccines ﻿

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. ﻿

Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood ﻿

Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid ﻿

Immunogenicity and Tolerability of a Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 12 Months of Age. ﻿

Kinetics and avidity of antibodies evoked by two pneumococcal conjugate vaccines, PncCRM.and PncOMPC, in the Finnish Otitis Media Vaccine Trial ﻿

Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants ﻿

Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children ﻿

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: Randomised, controlled trial of a sevenvalent pneumococcal polysaccharide-meningococcal outer membrane protein c ﻿

Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid ﻿

Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine ﻿

Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT ﻿

Streptococcus pneumoniae capsular polysaccharide - diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory ﻿

Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers ﻿